New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
15:51 EDTCAHEarnings Preview: Cardinal Health breaks short term uptrend into Q2 report
Cardinal Health (CAH) is scheduled to report Q2 earnings before the market open on Tuesday February 5, with a conference call scheduled for 8:30 am ET. Cardinal Health improves the cost-effectiveness of healthcare. As the business behind healthcare, Cardinal Health helps pharmacies, hospitals and ambulatory care sites focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability... EXPECTATIONS: Analysts are looking for EPS of 86c on revenue of $24.61B, according to First Call. The consensus range for EPS is 84c-88c on revenue of $24.22B-$25.04B... LAST QUARTER: Cardinal Health reported Q1 EPS of 81c against estimates of 79c on revenue of revenue $25.89B, against estimates of $26.35B. At the time of its Q1 results, Cardinal Health gave FY13 EPS guidance of $3.35-$3.50 on analysts consensus estimates of $3.45. The company backed that EPS view at the for J.P. Morgan Healthcare Conference on January 8... STREET RESEARCH: On January 23, RW Baird raised its price target on Cardinal Health shares to $52 from $50, citing earnings leverage, continued generics contributions, growth in platforms outside of drug distribution, and share repurchases. The firm has an Outperform rating on shares of the company... PRICE ACTION: Shares of Cardinal Health have traded lower, after announcing on January 30 that it expects to incur a $79M restructuring charge from a medical segment reorganization. In late afternoon trading, shares of Cardinal Health are trading down less than a percentage point at $43.66.
News For CAH From The Last 14 Days
Check below for free stories on CAH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 11, 2014
07:32 EDTCAHCardinal Health appoints Michael C. Kaufmann as CFO
Cardinal Health has named Michael C. Kaufmann, 51, CFO effective Nov. 11. This follows the previously announced planned retirement of current CFO Jeffrey W. Henderson, 49. Jon Giacomin, 49, has been named to the role of CEO of the Pharmaceutical segment, currently held by Mike Kaufmann, also effective Nov. 11.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use